| Telerehabilitation in stroke care–a systematic review T Johansson, C Wild Journal of telemedicine and telecare 17 (1), 1-6, 2011 | 346 | 2011 |
| Best practice in undertaking and reporting health technology assessments: Working Group 4 report R Busse, J Orvain, M Velasco, M Perleth, M Drummond, T Jørgensen, ... International journal of technology assessment in health care 18 (2), 361-422, 2002 | 284 | 2002 |
| Practical tools and methods for health technology assessment in Europe: Structures, methodologies, and tools developed by the European network for Health Technology Assessment … FB Kristensen, K Lampe, DL Chase, SH Lee-Robin, C Wild, M Moharra, ... International journal of technology assessment in health care 25 (S2), 1-8, 2009 | 129 | 2009 |
| Telemedicine in acute stroke management: systematic review T Johansson, C Wild International journal of technology assessment in health care 26 (2), 149-155, 2010 | 127 | 2010 |
| The HTA Core Model®—10 years of developing an international framework to share multidimensional value assessment FB Kristensen, K Lampe, C Wild, M Cerbo, W Goettsch, L Becla Value in Health 20 (2), 244-250, 2017 | 126 | 2017 |
| European network for Health Technology Assessment, EUnetHTA: Planning, development, and implementation of a sustainable European network for Health Technology Assessment FB Kristensen, M Mäkelä, SA Neikter, N Rehnqvist, LL Håheim, B Mørland, ... International journal of technology assessment in health care 25 (S2), 107-116, 2009 | 123 | 2009 |
| Strengthening vaccination programmes and health systems in the European Union: a framework for action L Siciliani, C Wild, M McKee, D Kringos, MM Barry, PP Barros, ... Health Policy 124 (5), 511-518, 2020 | 92 | 2020 |
| Evaluating and planning ICUs: methods and approaches to differentiate between need and demand C Wild, M Narath Health Policy 71 (3), 289-301, 2005 | 91 | 2005 |
| Best practice in undertaking and reporting health technology assessments. Working group 4 report M Velasco, M Perleth, M Drummond, F Gürtner, T Jørgensen, A Jovell, ... International journal of technology assessment in health care 18 (2), 361-422, 2002 | 86 | 2002 |
| Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials S Geiger-Gritsch, B Stollenwerk, R Miksad, B Guba, C Wild, U Siebert The oncologist 15 (11), 1179-1191, 2010 | 85 | 2010 |
| Extracorporeal shock wave therapy in orthopedics: Assessment of an emerging health technology C Wild, M Khene, S Wanke International journal of technology assessment in health care 16 (1), 199-209, 2000 | 84 | 2000 |
| Utilisation of the ESMO-MCBS in practice of HTA C Wild, N Grössmann, PV Bonanno, A Bucsics, J Furst, K Garuoliene, ... Annals of oncology 27 (11), 2134-2136, 2016 | 70 | 2016 |
| Emerging health technologies: informing and supporting health policy early C Wild, T Langer Health policy 87 (2), 160-171, 2008 | 69 | 2008 |
| Hospital managers’ need for information in decision-making–An interview study in nine European countries K Kidholm, AM Ølholm, M Birk-Olsen, A Cicchetti, B Fure, E Halmesmäki, ... Health Policy 119 (11), 1424-1432, 2015 | 68 | 2015 |
| Systematic review of the efficacy and safety of fibrinogen concentrate substitution in adults M Warmuth, P Mad, C Wild Acta anaesthesiologica scandinavica 56 (5), 539-548, 2012 | 68 | 2012 |
| Guiding principles for good practices in hospital-based health technology assessment units L Sampietro-Colom, K Lach, I Pasternack, JB Wasserfallen, A Cicchetti, ... International Journal of Technology Assessment in Health Care 31 (6), 457-465, 2015 | 67 | 2015 |
| Technology forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption C Eder, C Wild Journal of market access & health policy 7 (1), 1600939, 2019 | 65 | 2019 |
| Individual and institutional corruption in European and US healthcare: overview and link of various corruption typologies M Sommersguter-Reichmann, C Wild, A Stepan, G Reichmann, A Fried Applied health economics and health policy 16, 289-302, 2018 | 64 | 2018 |
| Mid-and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination … J Erdos, C Wild European Journal of Paediatric Neurology 39, 1-10, 2022 | 62 | 2022 |
| Health technology assessment of medical devices: what is different? An overview of three European projects P Schnell-Inderst, J Mayer, J Lauterberg, T Hunger, M Arvandi, ... Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 109 (4 …, 2015 | 60 | 2015 |
